GI Signals - Esophagus/Refluxhttps://siftingsignal.com/gisignals/Esophagus/Reflux papers worth knowing in GI this week. A SiftingSignal publication.The Eosinophilic Esophagitis Severity Index Reflects Response to Budesonide Orodispersible Tablets during Induction and Maintenance Therapy.https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42624389https://siftingsignal.com/gisignals/2026-W35/#card-pmid-42624389Mon, 24 Aug 2026 19:12:09 +0000Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. I-SEE (a composite severity index; specific calculation method is detailed in the source paper) can be used to assess baseline disease severity and monitor response to budesonide therapy at 12 weeks and 1 year. Higher baseline I-SEE indicates patients with fibrostenotic features and prior stricturing; consider early combined medical-endoscopic management in these higher-risk patients to address structural disease. Baseline I-SEE score does not predict loss of response during maintenance therapy.Urban Residency is Independently Associated With Allergic Phenotype and Inflammatory Changes in Eosinophilic Esophagitis.https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42008647https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42008647Thu, 06 Aug 2026 18:00:11 +0000Journal of clinical gastroenterology. Consider urban residency as a potential risk factor for more severe allergic phenotype and inflammatory findings in EoE patients, but no direct clinical action yet: this is an observational association.Gastroesophageal Reflux Disease and Reflux-like Phenotypes: Using Lyon Consensus 2.0 to Guide Clinical Approach.https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504650https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504650Thu, 06 Aug 2026 18:00:11 +0000Journal of neurogastroenterology and motility. Use Lyon 2.0 criteria to phenotype reflux-like symptoms in patients with unclear diagnoses after initial evaluation: manage mucosal injury with reflux treatment and surveillance; treat abnormal reflux burden with reflux therapy; address E-DGBI with functional disorder management. Assess for overlapping hypervigilance/anxiety. Specific reflux burden thresholds and criteria are detailed in the source.Potassium-competitive Acid Blockers in Gastroesophageal Reflux Disease and Functional Dyspepsia: A Korean Expert Review With Original Meta-analyses.https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504651https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504651Thu, 06 Aug 2026 18:00:11 +0000Journal of neurogastroenterology and motility. continue reserving P-CABs for confirmed GERD cases after PPI failure.Ineffective Esophageal Motility and Its Predictors in Gastroesophageal Reflux Disease Patients with Pathologic Acid Exposure Time.https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504658https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42504658Thu, 06 Aug 2026 18:00:11 +0000Journal of neurogastroenterology and motility. In GERD patients with pathologic acid exposure (AET >6%), further research is needed to determine if assessing for IEM with high-resolution manometry and MNBI leads to improved outcomes.Efficacy of a Dairy-Free Diet in Adult Patients With Eosinophilic Esophagitis: A Pilot Prospective Multicenter Study.https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42536060https://siftingsignal.com/gisignals/2026-W32/#card-pmid-42536060Thu, 06 Aug 2026 18:00:11 +0000Journal of gastroenterology and hepatology. May offer dairy-free diet as a simpler dietary option for adult EoE patients, particularly those averse to six-food elimination, while monitoring adherence in males/higher BMI patients and tempering expectations in those with prior dilations/severe inflammation.Gastroesophageal Reflux Disease and Reflux-like Phenotypes: Using Lyon Consensus 2.0 to Guide Clinical Approach.https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504650https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504650Thu, 30 Jul 2026 22:01:39 +0000Journal of neurogastroenterology and motility. Use Lyon 2.0 criteria to phenotype reflux-like symptoms in patients with unclear diagnoses after initial evaluation: manage mucosal injury with reflux treatment and surveillance; treat abnormal reflux burden with reflux therapy; address E-DGBI with functional disorder management. Assess for overlapping hypervigilance/anxiety. Specific reflux burden thresholds and criteria are detailed in the source.Potassium-competitive Acid Blockers in Gastroesophageal Reflux Disease and Functional Dyspepsia: A Korean Expert Review With Original Meta-analyses.https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504651https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504651Thu, 30 Jul 2026 22:01:39 +0000Journal of neurogastroenterology and motility. continue reserving P-CABs for confirmed GERD cases after PPI failure.Ineffective Esophageal Motility and Its Predictors in Gastroesophageal Reflux Disease Patients with Pathologic Acid Exposure Time.https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504658https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42504658Thu, 30 Jul 2026 22:01:39 +0000Journal of neurogastroenterology and motility. In GERD patients with pathologic acid exposure (AET >6%), further research is needed to determine if assessing for IEM with high-resolution manometry and MNBI leads to improved outcomes.Step-Down Dose Reduction Dupilumab Maintenance is an Effective Long-Term Treatment Strategy in Eosinophilic Esophagitis.https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42508792https://siftingsignal.com/gisignals/2026-W31/#card-pmid-42508792Thu, 30 Jul 2026 22:01:39 +0000Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Consider step-down dose reduction of dupilumab for long-term maintenance in eosinophilic esophagitis patients who achieve initial remission, provided they are stable and monitored for adverse events.Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42487340https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42487340Sat, 25 Jul 2026 22:16:33 +0000Journal of gastroenterology and hepatology. No intervention is tested. Observational study documents EoE and GERD are substantially more common in MASLD patients compared to matched controls without MASLD, but causation is unproven. No change to current screening or management algorithms; in a symptomatic MASLD patient, heightened clinical suspicion for EoE and GERD is reasonable pending mechanistic clarification.Efficacy of Proton Pump Inhibitor Therapy for Nocturnal GERD Symptoms and Associated Sleep Disturbances: A Systematic Review of Randomized Controlled Trials.https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42496003https://siftingsignal.com/gisignals/2026-W30/#card-pmid-42496003Sat, 25 Jul 2026 22:16:33 +0000Journal of clinical gastroenterology. Consider PPI therapy for adults with nocturnal GERD symptoms and associated sleep disturbances, especially if symptoms are reflux-driven, noting that treatment-emergent adverse events were similar to placebo.Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42437376https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42437376Sat, 18 Jul 2026 20:04:34 +0000Alimentary pharmacology & therapeutics. Screen hEDS/HSD patients for chronic GI symptoms (especially heartburn, dysphagia, GERD) following SOC for GERD (alarm feature assessment first, empiric PPI trial if no alarms). Assess for comorbid DGBIs (functional dysphagia 34.2%) and extraintestinal conditions (chronic fatigue 49%, migraine 38.2%, OI 35.9%, POTS 21.9%).Comparison of Fully Covered Self-Expanding Metal Stents and Liquid Nitrogen Spray Cryotherapy for Malignant Esophageal Adenocarcinoma: A Retrospective Cohort Study.https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42456982https://siftingsignal.com/gisignals/2026-W29/#card-pmid-42456982Sat, 18 Jul 2026 20:04:34 +0000Gastrointestinal endoscopy. In patients with malignant esophageal obstruction, particularly distal/GEJ lesions, consider LNSC over FCSEMS for palliation due to fewer adverse events, but monitor for delayed strictures. Reserve FCSEMS for cases requiring immediate luminal patency, acknowledging higher risk of migration/intolerance.Eosinophilic Esophagitis and Autoimmune Thyroid Disease: A Population-Based Matched Cohort Study.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42383463https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42383463Thu, 09 Jul 2026 16:47:07 +0000United European gastroenterology journal. Consider heightened awareness for AITD symptoms in childhood-onset EoE patients (HR 2.53 for future AITD, OR 4.71 for prior AITD). No routine screening recommended for adult-onset EoE (HR 1.18, 95% CI 0.91-1.54).Incidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study.https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42418075https://siftingsignal.com/gisignals/2026-W26/#card-pmid-42418075Thu, 09 Jul 2026 16:47:07 +0000Digestive diseases and sciences. Counsel patients with DM or obesity starting GLP-1 analogs about the high likelihood (1 in 3) of GI side effects, particularly nausea, vomiting, and GERD, and monitor for gastroparesis symptoms (early satiety, bloating). Note the reduced bowel obstruction risk and no significant increase in ER visits or hospitalizations despite higher EGD use.